Trend analysis of the pharmaceutical market in Iran; 1997-2010; policy implications for developing countries

DARU, Journal of Pharmaceutical Sciences

Volumn 21, Issue 1, 2013, Pages

  Kebriaeezadeh, Abbas ^a   Koopaei, Nasser Nassiri ^a   Abdollahiasl, Akbar ^a   Nikfar, Shekoufeh ^a   Mohamadi, Nafiseh ^b  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b Management Information System Division   (Iran)

Author keywords

Commercialization; Pharmaceutical biotechnology; Pharmaceutical market trends; Therapeutic categories

Indexed keywords

ARTICLE; BIOTECHNOLOGY; CROSS-SECTIONAL STUDY; DEVELOPING COUNTRY; DRUG COST; DRUG INDUSTRY; DRUG MANUFACTURE; DRUG MARKETING; GOVERNMENT; HEALTH CARE POLICY; IRAN; MEDICAL RESEARCH; REIMBURSEMENT;

EID: 84880817728     PISSN: 15608115     EISSN: 20082231     Source Type: Journal    
DOI: 10.1186/2008-2231-21-52     Document Type: Article

References (25)

1. Regulating health care in low- and middle-income countries: Broadening the policy response in resource constrained environments. Ensor T, Weinzierl S, Soc Sci Med 2007 65 355 366 (Pubitemid 46924855)
2. Kebrieezadeh A, Eslamitabar S, Khatibi M, Iranian pharmaceutical law and regulations Tehran: Razico 2 2009
3. An information infrastructure for the pharmaceutical market. Reinhardt UE, Health Aff 2004 23 1 107 112
4. Pharmaceutical policy and market in Iran: past experiences and future challenges. Davari M, Walley T, Haycox A, J Pharm Health Serv Res 2011 2 47 52
5. Pharmacoeconomics: An Effective Tool for Prioritization in Iran Healthcare System. Cheraghali AM, Iranian J Pharm Res 2008 7 2 89 91
6. Overview of National Drug Policy of Iran. Kebriee-zadeh A, IJPR 2003 1 2
7. Active pharmaceutical management strategies of health insurance systems to improve cost-effective use of medicines in low- and middle-income countries: A systematic review of current evidence. Faden L, Vialle-Valentin C, Ross-Degnan D, Wagner A, Health Policy 2011 100 134 143
8. Pharmaceutical Market. Cheraghali AM, IJPR 2006 1 1 7
9. Current trends in the pharmaceutical industry-A case study approach. Rusu A, Kuokkanen K, Heier A, Eur J Pharm Sci 2011 44 437 440
10. Strategic trends in the drug industry. Drews J, Drug Discov Today 2003 8 9 411 420 (Pubitemid 36438611)
11. Monitoring of National Drug Policy (NDP) and its standardized indicators; conformity to decisions of the National Drug Selecting Committee in Iran. Nikfar S, Kebriaeezadeh A, Majdzadeh R, Abdollahi M, BMC Int Health Hum Rights 2005 5 5
12. An overview of the Greek pharmaceutical market. Kontozamanis V, Mantzouneas E, Stoforos C, Eur J Health Econ 2003 4 327 333 (Pubitemid 38081999)
13. Trends in alternative medicine use in the United States, 1990-1997, results of a follow-up national survey. Eisenberg DM, Davis RB, Ettner SL, Appel S, Wilkey S, Rompay MV, et al. JAMA 1998 280 18 1569 1575 (Pubitemid 28520643)
14. The Turkish pharmaceutical market. Tokgöz T, JGM 2010 7 270 274
15. Providing affordable essential medicines to African households: The missing policies and institutions for price containment. Tetteh EK, Soc Sci Med 2008 66 569 581
16. Medicine prices, availability, and affordability in 36 developing and middle-income countries: a secondary analysis. Cameron A, Ewen M, Ross-Degnan D, Ball D, Laing R, Lancet 2009 373 240 249
17. The role of health technology assessment on pharmaceutical reimbursement in selected middle-income countries. Oortwijn W, Mathijssen J, Banta D, Health Policy 2010 95 174 184
18. Pharmaceutical industry in Syria. Kutaini D, J Med Life 2010 3 3 348 350
19. Pharmaceutical policy in Italy: towards a structural change? Ghislandi S, Krulichova I, Garattini L, Health Policy 2005 72 53 63 (Pubitemid 40349008)
20. A pricing policy towards the sourcing of cheaper drugs in Cyprus. Merkur S, Mossialos E, Health Policy 2007 81 368 375 (Pubitemid 46436194)
21. Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies. Aaserud M, Dahlgren AT, Kosters JP, Oxman AD, Ramsay C, Sturm H, Cochrane Database Syst Rev 2006 2
22. Evaluation of policies to support drug development in New Zealand. Lockhart M, Babar ZUD, Garg S, Health Policy 2010 96 108 117
23. Analysis of the pharmaceuticals market and its technological development in Turkey. Kisa A, Int J Technol Assess Health Care 2006 22 4 537 542 (Pubitemid 44622977)
24. Patterns of antibiotic consumption in Iran during 2000-2009. Abdollahiasl A, Kebriaeezadeh A, Nikfar S, Farshchi A, Ghiasi G, Abdollahi M, Int J Antimicrob Agents 2011 37 489 490
25. A model for developing a decision support system to simulate national drug policy indicators. Abdollahiasl A, Nikfar S, Kebriaeezadeh A, Dinarvand R, Abdollahi M, Arch Med Sci 2011 5 744 746